The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009.

Dated: October 16, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9–25889 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 16, 2009, American Radiolabeled Chemical, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Gamma Hydroxybutyric Acid (2010).	I
Ibogaine (7260)	I
Lysergic acid diethylamide (7315)	I
Tetrahydrocannabinols (7370)	I
Dimethyltryptamine (7435)	I
1-[1-(2-	
Thienyl)cyclohexyl]piperidine.	
(7470)	I
Dihydromorphine (9145)	I
Normorphine (9313)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Amobarbital (2125)	II
Phencyclidine (7471)	II
Phenylacetone (8501)	II
Cocaine (9041)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Ecgonine (9180)	II
Hydrocodone (9193)	II
Meperidine (9230)	II
Metazocine (9240)	11

Drug	Schedule
Dextropropoxyphene, bulk (non- dosage forms) (9273).	II
Morphine (9300) Oripavine (9330)	
Thebaine (9333) Oxymorphone (9652) Phenazocine (9715)	
Fentanyl (9801)	II

The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009.

Dated: October 16, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9–25884 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 26, 2009, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedule I:

Drug	Schedule
Marihuana (7360) Tetrahydrocannabinols (7370)	

The company plans to manufacture small quantities of marihuana derivatives for research purposes. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol. In reference to drug code 7370 (Tetrahydrocannabinols), the company

will manufacture a synthetic THC. No

other activity for this drug code is authorized for registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009.

Dated: October 16, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9–25899 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 27, 2009, Varian, Inc., Lake Forest, 25200 Commercentre Drive, Lake Forest, California 92630–8810, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Phencyclidine (7471) 1-Piperidinocyclohexan- carbonitrile (8603)	
Benzoylecgonine (9180)	П

The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009.

Dated: October 16, 2009.	Drug	Schedule	Drug	Schedule
Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of	Oxymorphone (9652)	11	Meperidine (9230)	11
Diversion Control, Drug Enforcement Administration.	The company plans to manu		Methadone (9250) Methadone intermediate (9254)	
[FR Doc. E9–25895 Filed 10–27–09; 8:45 am] BILLING CODE 4410-09–P	small quantities of the listed co substances to produce isotope		Morphine (9300) Thebaine (9333)	II II
BILLING CODE 4410-09-P	standards for drug testing and		Oxymorphone (9652)	II

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to §1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 9, 2009, Aldrich Chemical Company Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio 45342–4304, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Gamma Hydroxybutyric Acid (2010).	I
Methaqualone (2565)	1
Ibogaine (7260)	1
Tetrahydrocannabinols (7370)	1
2,5-Dimethoxyamphetamine	I
(7396).	
Psilocyn (7438)	1
Normorphine (9313)	I
Acetylmethadol (9601)	I
Alphacetylmethadol except levo-	I
alphacetylmethadol (9603).	
Normethadone (9635)	1
Norpipanone (9636)	
3-Methylfentanyl (9813)	
Amphetamine (1100)	
Methamphetamine (1105)	
Methylphenidate (1724)	
Amobarbital (2125) Pentobarbital (2270)	
Secobarbital (2315)	
1-Phenylcyclohexylamine (7460)	
Phencyclidine (7471)	
Phenylacetone (8501)	ii
1-Piperidinocyclohexane-	ii
carbonitrile (8603).	
Cocaine (9041)	II
Codeine (9050)	Ш
Oxycodone (9143)	II
Hydromorphone (9150)	II
Benzoylecgonine (9180)	II
Ethylmorphine (9190)	II
Hydrocodone (9193)	II
Isomethadone (9226)	II
Meperidine (9230)	
Meperidine intermediate-A (9232)	
Meperidine intermediate-B (9233)	
Methadone (9250)	
Methadone intermediate (9254)	
Dextropropoxyphene, bulk, (non-	II
dosage forms) (9273). Morphine (9300)	Ш
Thebaine (9333)	
Levo-alphacetylmethadol (9648)	
2010-alphacetyimethauor (3040)	

standards for drug testing and analysis.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive. Springfield, Virginia 22152; and must be filed no later than December 28, 2009.

Dated: October 20, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9-25893 Filed 10-27-09; 8:45 am] BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances: Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 10, 2009, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066-1742, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Gamma Hydroxybutyric Acid (2010).	I
Tetrahydrocannabinols (7370)	1
Dihydromorphine (9145)	1
Difenoxin (9168)	1
Propiram (9649)	1
Amphetamine (1100)	П
Methamphetamine (1105)	П
Lisdexamfetamine (1205)	П
Methylphenidate (1724)	11
Nabilone (7379)	П
Cocaine (9041)	П
Codeine (9050)	П
Dihydrocodeine (9120)	П
Oxycodone (9143)	П
Hydromorphone (9150)	П
Ecgonine (9180)	П
Hydrocodone (9193)	11

Drug	Schedule
Meperidine (9230) Methadone (9250) Methadone intermediate (9254) Morphine (9300) Thebaine (9333) Oxymorphone (9652) Noroxymorphone (9652) Noroxymorphone (9668) Alfentanil (9737) Remifentanil (9739) Sufentanil (9740) Fentanyl (9801)	

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a controlled substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive. Springfield, Virginia 22152; and must be filed no later than December 28, 2009.

Dated: October 21, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9-26002 Filed 10-27-09; 8:45 am] BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated June 15, 2009, and published in the Federal Register on June 23, 2009, (74 FR 29720), Noramco Inc., Division of Ortho-McNeil, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II.

The company plans to bulk manufacture the above listed controlled substance for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at